tiprankstipranks
Advertisement
Advertisement

Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205

Story Highlights
  • Harmony Biosciences announced preclinical data for BP1.15205, showing promising effects in narcolepsy models.
  • Human trials for BP1.15205 are planned for late 2025, with results anticipated in 2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205

Elevate Your Investing Strategy:

Harmony Biosciences Holdings ( (HRMY) ) just unveiled an update.

On June 11, 2025, Harmony Biosciences announced new preclinical data for BP1.15205, a promising orexin 2 receptor agonist, showing significant wake-promoting and cataplexy-suppressing effects in narcolepsy type 1 mouse models. The company plans to begin human trials in the latter half of 2025, with results expected in 2026, potentially enhancing its position in the sleep-wake disorder treatment market.

The most recent analyst rating on (HRMY) stock is a Sell with a $32.00 price target. To see the full list of analyst forecasts on Harmony Biosciences Holdings stock, see the HRMY Stock Forecast page.

Spark’s Take on HRMY Stock

According to Spark, TipRanks’ AI Analyst, HRMY is a Outperform.

Harmony Biosciences Holdings is performing strongly across multiple dimensions. The most significant factors are its robust financial performance and positive earnings call, which highlight strong growth, profitability, and a healthy pipeline. Technical indicators support a positive trend, while the fair valuation and positive corporate events further bolster the stock’s outlook. The combination of these factors results in a solid overall stock score.

To see Spark’s full report on HRMY stock, click here.

More about Harmony Biosciences Holdings

Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. Established in 2017 by Paragon Biosciences, the company is headquartered in Plymouth Meeting, Pennsylvania.

Average Trading Volume: 703,701

Technical Sentiment Signal: Buy

Current Market Cap: $2.06B

Learn more about HRMY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1